Fred Wagshul, MD
Family Health · Dayton, OHNPI 1336137595
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 303 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by Grifols USA, LLC at 29.6% of the total.
Across 303 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$2K
- AstraZeneca$943
- GSK$712
- Takeda Pharmaceuticals U.S.A., Inc.$401
- Mylan Specialty L.p.$352
- Boehringer Ingelheim$221
- plus $1K from 26 others
What the payments were for
- Food & beverage$5,351100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 93 | $1,586 |
| AstraZeneca | 42 | $943 |
| GSK | 52 | $712 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $401 |
| Mylan Specialty L.p. | 24 | $352 |
| Boehringer Ingelheim | 14 | $221 |
| Sanofi | 6 | $141 |
| Novo Nordisk | 7 | $131 |
| Mallinckrodt Hospital Products Inc. | 5 | $127 |
| Pulmonx Corporation | 2 | $74 |
| Verona Pharma, Inc. | 2 | $59 |
| Nabriva Therapeutics, PLC | 3 | $52 |
| Viatris Specialty LLC | 2 | $43 |
| Insmed, Inc. | 2 | $42 |
| Teva Pharmaceuticals USA, Inc. | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 3 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Circassia Inc. | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $31 |
| Pfizer | 2 | $30 |
| Shire North American Group Inc | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| AbbVie | 1 | $20 |
| Merck | 1 | $19 |
| Amgen | 1 | $17 |
| Philips North America LLC | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Baxter Healthcare | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $15 |
| Biogen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMBICORT$224
- FASENRA$122
- BREZTRI AEROSPHERE$101
How this compares
Too few family health providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $38,671 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,227 |
| Wixela InhubFluticasone Propion/Salmeterol | 11 | $2,747 |
| Azithromycin | 79 | $1,849 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 12 | $1,590 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $1,466 |
| Clarithromycin | 14 | $1,302 |
| Doxycycline Hyclate | 37 | $1,029 |
| Montelukast Sodium | 24 | $428 |
| Methylprednisolone | 33 | $200 |
| CefuroximeCefuroxime Axetil | 14 | $177 |
| Prednisone | 42 | $147 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $131 |
| Levothyroxine Sodium | 18 | $111 |
| Ciprofloxacin Hcl | 11 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $712 | $38,67136 claims |
| AstraZenecaSymbicort | $943 | $5,22718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few family health providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other family health in Dayton
- Juanita KrisherDayton$479
- Sheri DoddsLancaster$2K
- Lisa RitenourCanton$2K
- Vicki DelanyDublin$990
- Annette SaveskiMansfield$565
- Chasady FreezeBowling Green$405
- Elizabeth MitchellCincinnati$318
- Suvarnamala PushkaranMiddletown$150
- Kelley RhoadesZanesville$81
- Kirsten DodsonColumbus$68
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.